Behandling af synstruende diabetisk retinopati

Translated title of the contribution: Treatment of sight-threatening diabetic retinopathy

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

In diabetic retinopathy, treatment is indicated for sight-threatening complications like proliferative diabetic retinopathy (PDR) and diabetic macular oedema (DME). For decades, treatment has been with panretinal laser for PDR and focal/grid laser for DME. In recent years, intravitreal therapy with vascular endothelial growth factor (VEGF) inhibition or steroids has replaced laser treatment in centre-involving DME. Intravitreal VEGF-inhibition has also demonstrated effectiveness in PDR, but long-term studies are needed to address the concern of a potential continuous treatment burden.

Original languageDanish
Article numberV11170870
JournalUgeskrift for Laeger
Volume181
Issue number7
ISSN0041-5782
Publication statusPublished - 2019

Fingerprint

Diabetic Retinopathy
Vascular Endothelial Growth Factor A

Cite this

@article{90d68b765d4b4a85b4768f31f640f348,
title = "Behandling af synstruende diabetisk retinopati",
abstract = "In diabetic retinopathy, treatment is indicated for sight-threatening complications like proliferative diabetic retinopathy (PDR) and diabetic macular oedema (DME). For decades, treatment has been with panretinal laser for PDR and focal/grid laser for DME. In recent years, intravitreal therapy with vascular endothelial growth factor (VEGF) inhibition or steroids has replaced laser treatment in centre-involving DME. Intravitreal VEGF-inhibition has also demonstrated effectiveness in PDR, but long-term studies are needed to address the concern of a potential continuous treatment burden.",
keywords = "Angiogenesis Inhibitors/administration & dosage, Anti-Inflammatory Agents/administration & dosage, Diabetes Mellitus, Type 1/complications, Diabetes Mellitus, Type 2/complications, Diabetic Retinopathy/drug therapy, Humans, Intravitreal Injections, Laser Coagulation, Macular Edema/drug therapy",
author = "Jakob Grauslund",
year = "2019",
language = "Dansk",
volume = "181",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "7",

}

Behandling af synstruende diabetisk retinopati. / Grauslund, Jakob.

In: Ugeskrift for Laeger, Vol. 181, No. 7, V11170870, 2019.

Research output: Contribution to journalJournal articleResearchpeer-review

TY - JOUR

T1 - Behandling af synstruende diabetisk retinopati

AU - Grauslund, Jakob

PY - 2019

Y1 - 2019

N2 - In diabetic retinopathy, treatment is indicated for sight-threatening complications like proliferative diabetic retinopathy (PDR) and diabetic macular oedema (DME). For decades, treatment has been with panretinal laser for PDR and focal/grid laser for DME. In recent years, intravitreal therapy with vascular endothelial growth factor (VEGF) inhibition or steroids has replaced laser treatment in centre-involving DME. Intravitreal VEGF-inhibition has also demonstrated effectiveness in PDR, but long-term studies are needed to address the concern of a potential continuous treatment burden.

AB - In diabetic retinopathy, treatment is indicated for sight-threatening complications like proliferative diabetic retinopathy (PDR) and diabetic macular oedema (DME). For decades, treatment has been with panretinal laser for PDR and focal/grid laser for DME. In recent years, intravitreal therapy with vascular endothelial growth factor (VEGF) inhibition or steroids has replaced laser treatment in centre-involving DME. Intravitreal VEGF-inhibition has also demonstrated effectiveness in PDR, but long-term studies are needed to address the concern of a potential continuous treatment burden.

KW - Angiogenesis Inhibitors/administration & dosage

KW - Anti-Inflammatory Agents/administration & dosage

KW - Diabetes Mellitus, Type 1/complications

KW - Diabetes Mellitus, Type 2/complications

KW - Diabetic Retinopathy/drug therapy

KW - Humans

KW - Intravitreal Injections

KW - Laser Coagulation

KW - Macular Edema/drug therapy

M3 - Tidsskriftartikel

VL - 181

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 7

M1 - V11170870

ER -